Previous close | 10.54 |
Open | 10.31 |
Bid | 10.35 x 50000 |
Ask | 10.47 x 50000 |
Day's range | 10.31 - 10.31 |
52-week range | 9.41 - 27.92 |
Volume | |
Avg. volume | 604 |
Market cap | 1.383B |
Beta (5Y monthly) | 1.12 |
PE ratio (TTM) | N/A |
EPS (TTM) | N/A |
Earnings date | N/A |
Forward dividend & yield | 0.19 (1.77%) |
Ex-dividend date | 14 June 2024 |
1y target est | N/A |
Earnings results often indicate what direction a company will take in the months ahead. With Q1 now behind us, let’s have a look at Lovesac (NASDAQ:LOVE) and its peers.
Despite a flat performance over the last week, the United States stock market has seen an impressive 24% increase over the past year with earnings expected to grow by 15% annually. In such a thriving environment, undervalued small-cap stocks like AtriCure, which show promising insider actions, could present intriguing opportunities for investors looking for potential growth.
Amid a robust surge in the U.S. stock market, with major indices like the S&P 500 and Nasdaq 100 reaching new highs largely due to mega-cap tech companies, smaller cap stocks often present unique opportunities for discerning investors. Given the current economic climate and insider transactions, understanding what makes a small-cap stock potentially undervalued could be particularly timely.